Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
Clinical trial NCT05102071 · WITHDRAWN
Trial details
- NCT number
- NCT05102071
- Sponsor
- Boehringer Ingelheim
- Status
- WITHDRAWN
- Study type
- OBSERVATIONAL
- Start date
- 2021-11-01
- Primary completion
- 2022-06-15
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.